A duo of preclinical studies recently demonstrated a new way to ferry medicines past the blood-brain barrier. And other research is on the way.
A personal, handheld device emitting high-intensity ultraviolet light to disinfect areas by killing the novel coronavirus is now feasible, according to researchers at Penn State, the University of Minnesota and two Japanese universities.
There are two commonly employed methods to sanitize and disinfect areas from bacteria and viruses—chemicals or ultraviolet radiation exposure. The UV radiation is in the 200 to 300 nanometer range and known to destroy the virus, making the virus incapable of reproducing and infecting. Widespread adoption of this efficient UV approach is much in demand during the current pandemic, but it requires UV radiation sources that emit sufficiently high doses of UV light. While devices with these high doses currently exist, the UV radiation source is typically an expensive mercury-containing gas discharge lamp, which requires high power, has a relatively short lifetime, and is bulky.
The solution is to develop high-performance, UV light emitting diodes, which would be far more portable, long-lasting, energy efficient and environmentally benign. While these LEDs exist, applying a current to them for light emission is complicated by the fact that the electrode material also has to be transparent to UV light.
As countries around the world begin lifting pandemic lockdowns, researchers are entering a new phase of work — donning masks with their lab coats, staggering hours in laboratory spaces and taking shifts on shared instruments. Some universities have created detailed plans to track and test staff, and many have limited the capacity of indoor spaces and the flow of people through hallways and entrances. For others, post-lockdown plans are still taking shape. And whereas some universities have worked in lockstep with governments to formulate safety plans, others have charted their own paths.
As scientists around the world return to work, they’re encountering new safety rules and awkward restrictions — and sometimes writing the protocols themselves.
“What you see in these diseases of aging is often the sort of unintended consequences of a system that was absolutely awesome for the young, at the expense of the old.” — Ned David.
Once considered an unimportant curiosity, Z-DNA is now recognized to provide an on-the-fly mechanism to regulate how an RNA transcript is edited.
The Infant Gut Microbiome and Probiotics that Work.
Indian start-up Nugenics Research to commercialise “Elixir” after showing 54% age reversal in animal study.
KINSHASA (Reuters) — Authorities in Congo announced a new Ebola outbreak in the western city of Mbandaka on Monday, adding to another epidemic of the virus that has raged in the east since 2018.
Eli Lilly and AbCellera dosed the first patients in a Phase I study of a potential antibody treatment for COVID-19. The two companies were able to get their antibody candidate into the clinic within two months of announcing their collaboration in response to the global pandemic.
The announcement was made a day after it was announced that more than 6 million people across the globe have been infected with the virus, including 1.79 million in the United States. COVID-19 has been responsible for the deaths of more than 372,000 people, with nearly one-third (104,383) in the U.S.
Patients were dosed with LY-CoV555, a neutralizing IgG1 monoclonal antibody (mAb) directed against the spike protein of SARS-CoV-2. It is designed to block viral attachment and entry into human cells, which should neutralize the virus, and potentially prevent and treat COVID-19. Because it’s an antibody derived from the blood of a recovered patient, Eli Lilly said LY-CoV555 is the first potential new medicine specifically designed to attack SARS-CoV-2, the virus that causes COVID-19.
Circa 2015
Natural killer (NK) cells were discovered 40 years ago, by their ability to recognize and kill tumor cells without the requirement of prior antigen exposure. Since then, NK cells have been seen as promising agents for cell-based cancer therapies. However, NK cells represent only a minor fraction of the human lymphocyte population. Their skewed phenotype and impaired functionality during cancer progression necessitates the development of clinical protocols to activate and expand to high numbers ex vivo to be able to infuse sufficient numbers of functional NK cells to the cancer patients. Initial NK cell-based clinical trials suggested that NK cell-infusion is safe and feasible with almost no NK cell-related toxicity, including graft-versus-host disease. Complete remission and increased disease-free survival is shown in a small number of patients with hematological malignances. Furthermore, successful adoptive NK cell-based therapies from haploidentical donors have been demonstrated. Disappointingly, only limited anti-tumor effects have been demonstrated following NK cell infusion in patients with solid tumors. While NK cells have great potential in targeting tumor cells, the efficiency of NK cell functions in the tumor microenvironment is yet unclear. The failure of immune surveillance may in part be due to sustained immunological pressure on tumor cells resulting in the development of tumor escape variants that are invisible to the immune system. Alternatively, this could be due to the complex network of immune-suppressive compartments in the tumor microenvironment, including myeloid-derived suppressor cells, tumor-associated macrophages, and regulatory T cells. Although the negative effect of the tumor microenvironment on NK cells can be transiently reverted by ex vivo expansion and long-term activation, the aforementioned NK cell/tumor microenvironment interactions upon reinfusion are not fully elucidated. Within this context, genetic modification of NK cells may provide new possibilities for developing effective cancer immunotherapies by improving NK cell responses and making them less susceptible to the tumor microenvironment. Within this review, we will discuss clinical trials using NK cells with a specific reflection on novel potential strategies, such as genetic modification of NK cells and complementary therapies aimed at improving the clinical outcome of NK cell-based immune therapies.
Keywords: natural killer cells, adoptive cell therapy, immunotherapy, cancer, clinical trials, expansion, tumor microenvironment, genetic modifications.
Who has heard of mitochondrial medicine?
“We know that increased rates of mtDNA mutation cause premature aging,” said Bruce Hay, Professor of biology and biological engineering at the California Institute of Technology. “This, coupled with the fact that mutant mtDNA accumulates in key tissues such as neurons and muscle that lose function as we age, suggests that if we could reduce the amount of mutant mtDNA, we could slow or reverse important aspects of aging.”
This brings us to the second major development relevant to mitochondria in disease — that genetic technology is now at a point where the targeted removal of the problem mitochondrial genes can become the basis for clinical intervention. This is the implication of research that Hay and colleagues both at Caltech and the University of California at Los Angeles described in a paper published in the journal Nature Communications.
